The Technical Analyst
NeuroMetrix Inc [NURO]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
NeuroMetrix Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.68% $4.41
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.76 mill |
| EPS: | -6.27 |
| P/E: | -0.700 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 1.987 mill |
| Avg Daily Volume: | 0.0505 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.700 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.700 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.19 - 4.63 ( +/- 4.90%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Horowitz Joshua | Buy | 16 438 | Common Stock |
| 2024-04-18 | Horowitz Joshua | Buy | 0 | Common Stock |
| 2024-04-18 | Horowitz Joshua | Sell | 0 | Common Stock |
| 2024-04-01 | Higgins Thomas T | Buy | 469 | Common Stock |
| 2024-04-01 | Higgins Thomas T | Sell | 74 | Common Stock |
| INSIDER POWER |
|---|
| 54.29 |
| Last 97 transactions |
| Buy: 971 558 | Sell: 254 579 |
Forecast:
16:00 - $4.56
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.56
Forecast 2: 16:00 - $4.56
Forecast 3: 16:00 - $4.56
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.41 (0.68% ) |
| Volume | 0.0071 mill |
| Avg. Vol. | 0.0505 mill |
| % of Avg. Vol | 14.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NURO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NURO
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-19 08:00:00 - Press Release
Neurometrix Announces Steps Taken To Enhance Shareholder Value
Joshua s. horowitz joins board of directors at-the-market equity facility terminated woburn, mass., april 19, 2024 (globe newswire) -- neurometrix, inc. (nasdaq: nuro) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, ephraim fields of echo lake capital.
2024-03-14 09:00:00 - Press Release
Neurometrix Announces Publication Of Study Demonstrating That Dpncheck Accurately Diagnoses Diabetic Peripheral Neuropathy
Woburn, mass., march 14, 2024 (globe newswire) -- neurometrix, inc. (nasdaq: nuro) noted the recent publication of a large study demonstrating that dpncheck® combined with standard ekg or dpncheck alone accurately detects diabetic peripheral neuropathy (dpn).
2024-03-13 09:00:00 - Press Release
Neurometrix Announces That Over 2000 Patients With Fibromyalgia Have Been Prescribed Quell® Fibromyalgia
Neurometrix today announced that over 2000 fibromyalgia patients have been prescribed quell fibromyalgia since its strategic commercial launch in dec 2022.
2024-03-12 08:00:00 - Press Release
Echo Lake Capital Issues Top Ten List Of Reasons Why Shai Gozani, Ceo Of Neurometrix Inc., Should Be Fired
Nuro stock price has declined 99% since its ipo gozani has received compensation of over $10 million since the ipo gozani was charged by the ftc for various wrongdoings at nuro gozani apparently personally paid the ftc $4 million as part of a settlement gozani barely owns any nuro shares nuro continues to sell stock significantly below its net cash value new york, ny / accesswire / march 12, 2024 / earlier today echo lake capital sent a letter to the board of directors of neurometrix, inc. (nasdaq:nuro). the letter listed the top ten reasons why the board should immediately fire shai gozani, the company's longstanding chairman and ceo.
2024-03-04 08:00:00 - Press Release
Echo Lake Capital Calls For The Liquidation Of Neurometrix, Inc.
- stock trades significantly below its net cash per share - questions the board's ability and/or desire to create shareholder value - notes tremendous destruction of shareholder value under company's leadership - sees no reason for company to remain public new york, ny / accesswire / march 4, 2024 / on february 27, 2024, ephraim fields of echo lake capital filed a schedule 13d which included a letter to the board of directors of neurometrix, inc. (nasdaq:nuro). the letter described his belief that the company should immediately liquidate because its stock price is trading significantly below net cash and because mr.
Latest News
2024-02-22 11:55:19 - Seeking Alpha
NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript
2024-02-15 09:00:00 - GlobeNewsWire
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
2024-01-08 09:43:00 - GlobeNewsWire
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
NeuroMetrix announced today that the Company's Chairman and CEO, Dr. Shai N. Gozani will present at the Emerging Growth Conference on January 10, 2024.
2023-09-28 12:19:00 - GlobeNewsWire
NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023
WOBURN, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on October 4, 2023.
2023-08-30 09:00:00 - GlobeNewsWire
NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023
WOBURN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on September 6, 2023. This live, interactive, online event will give shareholders and the investment community the opportunity to interact in real time with the Company's Chairman and Chief Executive Officer, Dr. Shai N. Gozani. Dr. Gozani will present business highlights and recent developments, including the evolution of its Quell® neuromodulation technology. He will be available for questions from conference participants.
2023-07-20 13:00:00 - GlobeNewsWire
NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call
WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on July 27, 2023.
2023-05-03 12:41:02 - Seeking Alpha
NeuroMetrix, Inc. (NURO) Q1 2023 Earnings Call Transcript
NeuroMetrix, Inc. (NASDAQ:NURO ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Thomas Higgins - SVP, CFO & Treasurer Shai Gozani - Founder, Chairman, CEO, President & Secretary Conference Call Participants Operator Good morning, and welcome to the NeuroMetrix First Quarter 2023 Earnings Call. My name is Levay, and I'll be your moderator on the call.
2023-04-28 09:21:00 - GlobeNewsWire
NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call
WOBURN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on May 3, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on May 3, 2023 to discuss its financial results as well as business developments affecting the Company.
2023-02-23 17:23:05 - Seeking Alpha
NeuroMetrix, Inc. (NURO) Q4 2022 Earnings Call Transcript
NeuroMetrix, Inc. (NASDAQ:NURO ) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ET Company Participants Thomas Higgins - Senior VP, CFO & Treasurer Shai Gozani - Founder, Chairman, CEO, President & Secretary Conference Call Participants Jarrod Cohen - Cohen Operator Good morning, and welcome to the NeuroMetrix Fourth Quarter and Full Year 2022 Earnings Call. My name is Latanya, and I will be your moderator on the call.
2023-02-16 14:58:00 - GlobeNewsWire
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on February 23, 2023 to discuss its financial results as well as business developments affecting the Company.